Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXTAGE phase I/II study of zemocimig in healthy volunteers and patients with hemophilia A
jRCT2080224835Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2 trial of zemocimig in hemophilia A (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability, Pharmacokinetics and 2 more. Started Aug 2019; status: completed.
02
Drugs
zemocimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2080224835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224835.